stockportfolio.pro
Stocks / MESO vs STOK
MESO vs STOK
Mesoblast Limited and Stoke Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Mesoblast Limited (MESO) | Stoke Therapeutics, Inc. (STOK) | |
|---|---|---|
| Market cap | $1.8B | $1.8B |
| Revenue (latest FY) | $17.20M | $184.42M |
| Net income (latest FY) | $-102.14M | $-6.88M |
| Revenue growth (5y CAGR) | 19.0% | — |
| Net margin | -593.9% | -3.7% |
| Return on equity | -17.1% | -2.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MESO — free Open STOK — freeFrequently asked questions
Which is bigger, MESO or STOK?
Stoke Therapeutics, Inc. is larger by market capitalization — $1.8B versus $1.8B.
Which grows faster, MESO or STOK?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.